BioCentury | Aug 28, 2020
Regulation

Biotech may have side-stepped CFIUS’ worst case scenario

So far, biotech has avoided the nightmare scenario in which almost any private company seeking foreign investment would come under government scrutiny. Recently proposed legislation could inject additional...
BioCentury | Jun 8, 2020
Deals

Why an AZ-Gilead megadeal doesn’t make sense for investors

While neither AstraZeneca nor Gilead has quashed rumors of merger discussions that circulated over the weekend, investors in both companies should hope the chatter amounts to nothing. Both companies declined to comment on a Bloomberg...
BioCentury | Jan 18, 2020
Product Development

Charting a course to intercepting Type I diabetes

Arguably, the most important innovations on the horizon for Type I diabetes would replace the insulin-producing cells patients have lost or prevent at-risk individuals from losing the cells in the first place. With Provention planning...
BioCentury | Jan 8, 2020
Politics, Policy & Law

Over 200 biopharma leaders endorse commitment to patients and the public

Dismayed by their industry’s abysmal reputation, leaders of small and medium-sized biotechs are taking rebuilding public trust into their own hands. Led by six CEOs, executives representing over 150 companies have signed an open letter...
BioCentury | Dec 6, 2019
Targets & Mechanisms

Bispecifics and allogeneics steal the spotlight from autologous CAR Ts

Standing out at this year's ASH meeting is a pair of growing threats to first-generation CAR T cell therapies: bispecific antibodies and allogeneic cell therapies. Gone are the days when autologous CAR Ts were the...
BioCentury | Nov 7, 2019
Clinical News

AML, safety data for magrolimab help Forty Seven shares regain ground

Business: Cancer After disappointing investors with its first data on anti-CD47 mAb magrolimab in May, Forty Seven gained $1.20 (18%) to $8.01 on Wednesday with updated data showing slight improvements in AML response rates and...
BioCentury | Oct 18, 2019
Finance

Accelmed’s $100M fund targets early stage digital health plays

Israeli fund group Accelmed has launched a $100 million fund to invest in health-tech companies it views as attractive takeover targets. Accelmed Ventures II will focus on prerevenue med-tech and digital health companies in Israel...
BioCentury | Oct 3, 2019
Targets & Mechanisms

ALS platform trial to put neuroinflammation hypothesis to the test

The largest test of the idea that ALS is driven by neuroinflammation will come from the first collaborative platform trial in the disease, which could blow open the range of pathways and targets in play...
BioCentury | Aug 10, 2019
Product Development

Eat this, don’t eat that: CD47 companies’ first hurdle

The rush to drug CD47 shows no signs of abating, with five companies launching clinical programs for cancer this year and three moving forward on the back of encouraging Phase I data. The differentiator may...
BioCentury | Aug 6, 2019
Clinical News

Next up for GlycoMimetics after tanking in sickle cell disease

Despite plunging 69% to $2.80 on Monday after the Phase III miss of sickle cell disease candidate rivipansel, GlycoMimetics could still turn things around. The small cap has another shot on goal with Phase III...
Items per page:
1 - 10 of 287